SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Enclomiphene / Enclomifene | Human Chorionic Gonadotropin (hCG) | Follitropin alfa |
|---|---|---|---|
| Research Topic | Reproductive Endocrinology | Reproductive Endocrinology | Reproductive Endocrinology |
| Pharmacology | Selective estrogen receptor modulator / clomiphene isomer | Placental glycoprotein hormone and LH/hCG-receptor agonist gonadotropin | Recombinant human follicle-stimulating hormone glycoprotein |
| PrimeCore Class | Class BInvestigational | Class AApproved in a bounded context | Class AApproved in a bounded context |
| Evidence Grade | Grade CEarly human evidence | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Enclomiphene is a clomiphene isomer, not testosterone or the full clomiphene mixture. Trials reported hormone and sperm-count effects, but these do not establish symptom or live-birth benefit. EMA refused EnCyzix in 2018, citing insufficient symptom evidence and venous-thromboembolism concerns. | A placental glycoprotein hormone with product-specific prescription uses in reproductive medicine and selected endocrine contexts. Urine-derived Pregnyl, recombinant Ovidrel, endogenous hCG and online weight-loss products are not interchangeable; hCG is not FDA-approved for weight loss. | A recombinant human FSH glycoprotein with product-specific infertility indications in women and men. GONAL-f approvals do not make it interchangeable with menotropins, hCG, other follitropins or unverified products, and specialist monitoring remains essential. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations | English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
| Insufficient data in the current dataset | Insufficient data in the current dataset |
| Sources |
|
| |
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions